Synthetic Biologics, Inc. SYN Balance Sheet

Synthetic biologics, inc. (SYN)

Balance Sheet / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Dec'10
Assets
Current Assets
Cash and cash equivalents
10,085	15,045	18,650	21,712	24,694	28,918	9,549	7,129	11,037	17,116	21,050	13,376	13,471	19,055	4,549	10,049	15,100	20,818	31,806	4,757	12,049	17,525	3,286	7,843	11,155	14,625	-	-	-	9,954	-	-	-	-	4,608	8,385	-
Cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,145	6,877	8,520	-	4,577	5,932	6,802	6,678	-	-	2,649
Short-term investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,865	-	-
Accounts receivable - net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	122	245	440	405	494	444	339
Prepaid expenses and other current assets
1,084	1,381	1,193	1,298	860	593	559	535	606	827	1,263	1,540	3,366	2,515	3,091	5,774	7,116	9,519	10,331	6,955	1,574	1,548	1,382	1,389	1,332	1,591	1,647	1,880	2,234	2,509	-	-	-	16	-	-	-
Note receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	700	700	-	-	-	-	-	-	-	-
Other
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	151	94	83	-	123	75	343
Assets of discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	23	-	-	214
Total Current Assets
11,169	16,426	19,843	23,010	25,554	29,511	10,108	7,664	11,643	17,943	22,313	14,916	16,837	21,570	7,640	15,823	22,216	30,337	42,137	11,712	13,623	19,073	4,668	9,232	12,487	16,216	6,792	9,457	11,454	12,463	4,850	6,271	7,325	7,122	8,093	8,906	3,545
Property and equipment, net
309	367	425	485	545	607	665	731	801	872	943	800	859	905	582	482	501	494	483	107	75	65	67	51	38	37	157	155	215	223	249	254	303	323	371	396	475
Right of use asset
386	419	451	481	510	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long-term note receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	700	700	700	700	0	-	-	-
Goodwill
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	178	178	-
Deposits and other assets
23	23	23	23	23	23	23	23	23	23	23	24	23	23	26	26	26	14	14	18	18	6	6	6	6	4	4	15	15	37	27	20	21	31	32	40	91
Total Assets
11,887	17,235	20,742	23,999	26,632	30,141	10,796	8,418	12,467	18,838	23,279	15,740	17,719	22,498	8,248	16,331	22,743	30,845	42,634	11,837	13,716	19,144	4,741	9,289	12,531	16,257	6,953	9,627	11,684	13,423	5,826	7,245	8,349	7,476	8,675	9,520	4,111
Liabilities and Stockholders' Deficit
Current Liabilities:
Accounts payable
1,247	2,315	2,452	1,523	766	1,034	879	1,217	1,493	2,020	1,097	1,723	3,796	1,993	4,242	4,556	4,597	4,413	6,026	8,686	1,559	996	873	1,079	773	142	584	213	196	395	390	278	316	388	193	286	266
Accrued expenses
1,062	1,776	2,321	1,544	1,630	919	1,485	1,000	1,058	1,526	2,070	1,750	2,134	2,627	1,490	1,841	946	297	244	1,615	2,646	1,298	111	153	0	882	-	16	-	0	27	117	127	29	41	22	210
Warrant liabilities
-	-	-	-	0	-	19	645	1,428	4,083	12,664	7,573	9,731	14,821	6,886	7,552	11,065	10,567	10,662	14,803	10,908	6,756	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-
Accrued employee benefits
309	935	619	511	341	1,332	1,434	1,362	1,016	2,074	1,606	1,209	787	313	1,341	1,174	869	277	314	394	228	538	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-
Deferred rent
-	-	0	0	0	99	97	95	92	90	88	75	40	3	51	50	49	21	55	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lease liability
258	249	241	233	225	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities of discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	24
Warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	88	-
Current portion of capital lease
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-
Total Current Liabilities
2,876	5,275	5,633	3,811	2,962	3,384	3,914	4,319	5,087	9,793	17,525	12,330	16,488	19,757	14,010	15,173	17,526	15,575	17,301	25,498	15,341	9,588	984	1,232	773	1,027	-	229	196	395	417	395	443	417	234	397	500
Deferred rent - Long term
-	-	0	0	0	302	329	353	377	402	426	448	470	492	214	227	240	267	198	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lease liability - Long term
405	473	539	601	662	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	2	32
Total Liabilities
3,281	5,748	6,172	4,412	3,624	3,686	4,243	4,672	5,464	10,195	17,951	12,778	16,958	20,249	14,224	15,400	17,766	15,842	17,499	25,498	15,341	9,588	984	-	773	1,027	584	229	-	395	417	395	443	417	236	400	532
Commitments and Contingencies
-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	0	0	0	0	0	-	-	-	0	-	-	-	0	-	0	-	-	-	-	-
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 120,000 issued and outstanding
12,606	12,544	12,481	12,419	12,357	12,296	12,234	12,173	-	12,053	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stockholders' Deficit:
Series B convertible preferred stock, $1,000 par value; 10,000,000 shares authorized, 6,565 issued and outstanding and 7,638 issued and outstanding
-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Common stock, $0.001 par value; 200,000,000 shares authorized, 17,741,803, issued and 17,739,475 outstanding and 16,808,758, issued and 16,806,430 outstanding
18	17	17	17	16	15	5	130	129	4	129	128	118	117	92	91	91	91	91	73	73	72	58	58	58	58	45	45	45	44	33	33	33	31	28	27	23
Additional paid-in capital
233,735	232,580	232,485	232,211	231,817	230,754	200,807	194,186	193,230	192,670	192,042	183,837	177,331	175,762	165,091	163,508	161,791	160,739	159,574	113,289	111,702	110,526	98,261	97,651	96,796	96,430	83,358	83,019	82,612	81,925	62,251	61,762	60,946	58,901	57,099	56,683	47,280
Accumulated deficit
-238,967	-235,537	-232,394	-227,141	-223,432	-219,461	-204,545	-200,803	-196,545	-194,170	-196,959	-179,135	-174,880	-172,034	-169,659	-161,305	-155,624	-144,779	-133,797	-127,023	-113,400	-101,042	-94,562	-89,652	-85,096	-81,258	-77,034	-73,666	-71,169	-68,941	-56,875	-54,945	-53,073	-51,873	-48,688	-47,590	-43,724
Total Synthetic Biologics, Inc. and Subsidiaries Deficit
-1,122	1,821	4,930	10,022	13,523	17,068	-3,733	-6,487	-3,186	-1,496	-4,788	4,830	2,569	3,845	-4,476	2,294	6,258	16,051	25,868	-13,661	-1,625	9,556	3,757	8,057	11,758	15,230	6,369	9,398	11,488	13,028	5,409	6,850	7,906	7,059	8,438	9,120	3,579
Non-controlling interest
-2,878	-2,878	-2,841	-2,854	-2,872	-2,909	-1,948	-1,940	-1,923	-1,914	-1,876	-1,868	-1,808	-1,596	-1,500	-1,363	-1,281	-1,048	-733	0	0	0	0	0	0	0	-	-	-	0	-	-	-	-	-	-	-
Total Stockholders' Deficit
-4,000	-1,057	2,089	7,168	10,651	14,159	-5,681	-8,427	-5,109	-3,410	-6,664	2,962	761	2,249	-5,976	931	4,977	15,003	25,135	-13,661	-1,625	9,556	3,757	8,057	11,758	15,230	-	-	-	13,028	-	-	-	-	-	-	-
Total Liabilities and Stockholders' Deficit
11,887	17,235	20,742	23,999	26,632	30,141	10,796	8,418	12,467	18,838	23,279	15,740	17,719	22,498	8,248	16,331	22,743	30,845	42,634	11,837	13,716	19,144	4,741	9,289	12,531	16,257	6,953	9,627	11,684	13,423	5,826	7,245	8,349	7,476	8,675	9,520	4,111
Series B Preferred Stock [Member]
Series B convertible preferred stock, $1,000 par value; 10,000,000 shares authorized, 6,565 issued and outstanding and 7,638 issued and outstanding
4,092	4,761	4,822	4,935	5,122	5,760	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Stockholders' Deficit
4,092	4,761	4,822	4,935	5,122	5,760	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-